📗 Cite This Artifact
BMPR2 Gene
BMPR2 Gene
Overview
The BMPR2 (Bone Morphogenetic Protein Receptor Type 2) gene encodes a constitutively active type II serine/threonine kinase receptor that plays critical roles in Bone Morphogenetic Protein (BMP) signaling pathways [@uzdens2018]. BMPR2 is essential for transducing extracellular BMP signals in partnership with type I receptors (BMPR1A/ALK3 or BMPR1B/ALK6), regulating diverse cellular processes including proliferation, differentiation, apoptosis, and inflammation [@cheng2013].
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">BMPR2 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>BMPR2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Bone Morphogenetic Protein Receptor Type 2</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>2q33.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[659](https://www.ncbi.nlm.nih.gov/gene/659)</td></tr>
<tr><td><strong>OMIM</strong></td><td>600799</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000153208</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q13873](https://www.uniprot.org/uniprot/Q13873)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Hereditary Pulmonary Arterial Hypertension, Fibrodysplasia Ossificans Progressiva</td></tr>
</table>
</div>
Molecular Biology and Signal Transduction
...
BMPR2 Gene
Overview
The BMPR2 (Bone Morphogenetic Protein Receptor Type 2) gene encodes a constitutively active type II serine/threonine kinase receptor that plays critical roles in Bone Morphogenetic Protein (BMP) signaling pathways [@uzdens2018]. BMPR2 is essential for transducing extracellular BMP signals in partnership with type I receptors (BMPR1A/ALK3 or BMPR1B/ALK6), regulating diverse cellular processes including proliferation, differentiation, apoptosis, and inflammation [@cheng2013].
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">BMPR2 Gene</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>BMPR2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Bone Morphogenetic Protein Receptor Type 2</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>2q33.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[659](https://www.ncbi.nlm.nih.gov/gene/659)</td></tr>
<tr><td><strong>OMIM</strong></td><td>600799</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000153208</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q13873](https://www.uniprot.org/uniprot/Q13873)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Hereditary Pulmonary Arterial Hypertension, Fibrodysplasia Ossificans Progressiva</td></tr>
</table>
</div>
Molecular Biology and Signal Transduction
Receptor Structure and Activation
BMPR2 is a 1038-amino acid transmembrane receptor consisting of:
- Extracellular domain: Ligand-binding region with cysteine-rich domain
- Transmembrane domain: Single-pass helix anchoring the receptor
- Intracellular serine/threonine kinase domain: Catalytic domain for signal transduction
BMPR2 functions as a constitutively active type II receptor. Upon ligand binding (BMP2, BMP4, or BMP6), BMPR2 recruits and phosphorylates type I receptors (ALK3/BMPR1A or ALK6/BMPR1B), initiating downstream signaling cascades [@mark2015].
SMAD-Dependent Signaling Pathway
The primary BMP signal transduction pathway involves SMAD proteins:
SMAD-Independent Pathways
BMPR2 also activates SMAD-independent signaling cascades:
- MAPK pathways: ERK, JNK, and p38 MAPK signaling
- PI3K/AKT pathway: Cell survival and metabolic regulation
- Rho GTPases: Cytoskeletal organization and cell migration
Role in Neuroinflammation
Microglial Activation
BMPR2 plays a crucial role in regulating microglial activation and neuroinflammation [@tang2017]. The BMP-SMAD signaling pathway modulates the neuroinflammatory response through:
- Pro-inflammatory mediator regulation: BMPR2 signaling modulates expression of TNF-α, IL-1β, IL-6, and COX-2
- Microglial phenotype switching: The pathway influences the M1/M2 polarization balance
- Nitric oxide production: BMPR2 regulates iNOS expression and nitric oxide synthesis
Dysregulated BMPR2 signaling in microglia contributes to chronic neuroinflammation, a hallmark of neurodegenerative diseases.
Astrocyte Function
BMPR2 is expressed in astrocytes and regulates their function [@wang2019]:
- Reactive astrogliosis: BMP signaling modulates astrocyte activation in response to injury
- Neuroprotective factor release: BMPR2 signaling influences secretion of neurotrophic factors
- Blood-brain barrier maintenance: Astrocytic BMPR2 supports BBB integrity
Neuroinflammatory Signaling Networks
BMPR2 interacts with key neuroinflammatory pathways:
- NF-κB pathway: Cross-talk between BMP and NF-κB signaling modulates inflammatory responses
- TGF-β signaling: BMPR2 shares downstream effectors with TGF-β receptors
- Wnt signaling: BMP-Wnt cross-regulation in neural stem cell niches
Role in Neurodegenerative Diseases
Alzheimer's Disease
BMPR2 dysfunction contributes to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis through multiple mechanisms [@yang2018]:
Amyloid-Beta Pathology
BMP-SMAD signaling is involved in amyloid-beta metabolism and toxicity [@zhang2017]:
- BMP signaling regulates amyloid precursor protein (APP) processing
- SMAD complexes interact with APP gene promoters
- Dysregulated BMP signaling enhances amyloid-beta-induced neurotoxicity
The BMP-SMAD pathway intersects with tau pathology in AD [@costa2019]:
- SMAD signaling influences tau phosphorylation
- BMP2 modulates GSK-3β activity, a key tau kinase
- Altered BMP signaling contributes to neurofibrillary tangle formation
BMPR2 signaling is essential for synaptic plasticity and memory formation [@yang2020]:
- BMP-SMAD pathway regulates synaptic protein expression
- Impaired BMPR2 signaling contributes to synaptic loss
- The pathway modulates long-term potentiation (LTP)
Targeting BMPR2 signaling for AD therapy has been explored [@ma2019]:
- BMP signaling modulators may protect against amyloid toxicity
- Enhancing SMAD signaling could reduce neuroinflammation
- Gene therapy approaches to restore BMPR2 function are under investigation
Parkinson's Disease
In [Parkinson's disease](/diseases/parkinsons-disease), BMPR2 plays complex roles in dopaminergic neuron survival [@liu2019]:
Dopaminergic Neuroprotection
BMP signaling protects dopaminergic neurons [@zhao2016]:
- BMP2 and BMP6 promote dopaminergic neuron survival
- SMAD signaling upregulates anti-oxidant enzymes
- BMP pathway activation reduces MPTP-induced toxicity
The BMP-SMAD pathway interacts with alpha-synuclein pathology [@hou2018]:
- BMP signaling modulates alpha-synuclein aggregation
- SMAD proteins regulate SNCA gene expression
- Dysregulated BMP signaling may enhance fibril formation
BMPR2 contributes to neuroinflammation in PD:
- Microglial BMP signaling regulates cytokine production
- The pathway modulates glial cell activation
- Targeting BMP signaling may reduce neuroinflammation
Amyotrophic Lateral Sclerosis
BMPR2 signaling may play roles in ALS:
- Motor neuron survival depends on BMP signaling
- Dysregulated BMP pathway in astrocyte reactivity
- Potential therapeutic target for motor neuron protection
Expression Patterns in the Brain
Regional Distribution
BMPR2 exhibits region-specific expression in the [central nervous system](/brain-regions/):
- High expression: [Substantia nigra](/brain-regions/substantia-nigra), [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), [basal ganglia](/brain-regions/basal-ganglia)
- Moderate expression: [Cerebellum](/brain-regions/cerebellum), [thalamus](/brain-regions/thalamus), [hypothalamus](/brain-regions/hypothalamus)
- Lower expression: Spinal cord
Cellular Localization
BMPR2 is expressed in multiple neural cell types:
- Neurons: Throughout the brain, particularly in pyramidal neurons and dopaminergic neurons
- Astrocytes: Reactive astrocytes show altered BMPR2 expression
- Microglia: Activated microglia exhibit dynamic BMPR2 regulation
- Oligodendrocytes: BMPR2 in oligodendrocyte precursor cells
Subcellular Distribution
- Plasma membrane: Primary location for receptor signaling
- Cytoplasm: Internalization and endosomal signaling
- Nucleus: SMAD-independent transcriptional regulation
Clinical Significance
Pulmonary Arterial Hypertension
The most well-established disease association of BMPR2 is hereditary pulmonary arterial hypertension (PAH) [@liu2020]:
- Inheritance: Autosomal dominant with incomplete penetrance
- Mechanism: Heterozygous mutations cause haploinsufficiency
- Penetrance: ~20% for males, ~80% for females
- Treatment: Vasodilators, gene therapy approaches
Fibrodysplasia Ossificans Progressiva
BMPR2 (actually BMPR1A) variants are associated with FOP:
- Classic FOP: ACVR1/ALK2 mutations
- BMPR2 role: Modifier gene in FOP severity
Neurodegenerative Disease Risk
Emerging evidence suggests BMPR2 variants may influence neurodegeneration:
- Reduced BMP signaling in aged brains
- Association with sporadic AD and PD
- Modifier of disease progression
Therapeutic Implications
Drug Development Targets
Gene Therapy Approaches
- AAV-mediated BMPR2 delivery: Restore receptor expression
- CRISPR-based correction: Repair pathogenic mutations
- RNA therapeutics: Increase BMPR2 mRNA stability
Repurposing Opportunities
Existing drugs targeting BMP signaling:
- Luspatercept: SMAP/SMAD pathway modifier
- Patriumab: BMP pathway inhibitor
- DMH1: BMP type I receptor inhibitor
Interactions and Network
Protein Interaction Partners
BMPR2 interacts with key proteins:
| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| BMPR1A | Type I receptor | Signal transduction |
| BMPR1B | Type I receptor | Signal transduction |
| SMAD1/5/8 | Substrate | Gene regulation |
| SMAD4 | Co-factor | Complex formation |
| FKBP12 | Regulatory | Receptor trafficking |
| TAB1 | Signaling adaptor | MAPK activation |
Signaling Network Integration
BMPR2 intersects with multiple pathways:
- TGF-β signaling: Shared SMAD effectors
- Wnt/β-catenin: Cross-talk in neural development
- Notch signaling: Combinatorial signaling in neural stem cells
- mTOR pathway: Metabolic regulation
Research Directions
Current Research Focus
Active areas of BMPR2 research in neurodegeneration include:
- Single-cell analysis: BMPR2 expression across neural cell types
- Epigenetic regulation: DNA methylation and histone modifications of BMPR2 [@sun2018]
- Biomarker development: BMPR2 as progression marker
Knowledge Gaps
Key questions remaining:
- How does BMPR2 dysfunction contribute to specific proteinopathies?
- What are the cell-type-specific roles of BMPR2 in neurodegeneration?
- Can BMP signaling modulators achieve CNS penetration?
See Also
- [BMP Signaling Pathway](/mechanisms/bmp-signaling-pathway)
- [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-overview)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [SMAD Proteins](/mechanisms/smad-signaling)
- [TGF-beta Signaling](/mechanisms/tgf-beta-signaling)
Signaling Pathways in Detail
Cross-Talk with Other TGF-β Family Members
BMPR2 does not function in isolation but participates in extensive cross-talk with other TGF-β superfamily members:
BMP Signaling Network:
- BMPR2 can signal through multiple BMP ligands (BMP2, BMP4, BMP6, BMP7, BMP9, BMP10)
- Each ligand-receptor combination produces distinct biological outcomes
- Ligand concentration gradients determine tissue patterning
- Antagonists (Noggin, Chordin, Follistatin) modulate signaling intensity
- BMPR2 can form heterodimeric complexes with TGF-β type I receptors
- This cross-talk allows integration of BMP and TGF-β signals
- Shared SMAD effectors (SMAD2/3 vs SMAD1/5/8) provide signal specificity
Non-SMAD Signaling Integration
Beyond canonical SMAD signaling, BMPR2 interacts with several other pathways:
MAPK/ERK Pathway:
- BMPR2 activates ERK1/2 through RAF-1
- ERK activation is critical for neuronal differentiation
- Cross-talk with neurotrophic factor signaling (BDNF, NGF)
- ERK activity is dysregulated in both AD and PD brains
- BMPR2 can activate AKT through PDK1
- AKT signaling promotes neuronal survival
- This pathway intersects with insulin-like growth factor signaling
- AKT dysregulation is a hallmark of many neurodegenerative conditions
- BMPR2 modulates stress-activated kinase pathways
- These pathways mediate inflammatory responses
- Their activation can lead to either pro-survival or pro-apoptotic outcomes depending on context
Calcium Signaling Integration
BMPR2 signaling intersects with calcium-dependent pathways:
- Calcium influx: BMP stimulation can modulate voltage-gated calcium channels
- Calmodulin interactions: Calcium-bound calmodulin can regulate SMAD function
- Calcium-activated proteases: Calpains may cleave BMPR2 under stress conditions
- NMDA receptor modulation: BMP signaling can affect NMDA receptor function
Clinical Genetics
Mutation Spectrum in Pulmonary Hypertension
Over 300 pathogenic BMPR2 mutations have been identified in PAH patients:
Types of mutations:
- Truncating mutations (40%): Nonsense, frameshift, splice-site
- Missense mutations (35%): Often affect kinase domain function
- Large deletions (10%): Exonic deletions detected by MLPA
- Splice mutations (15%): Alternative splicing leading to aberrant proteins
- Exon 2-4: Extracellular domain
- Exon 6-8: Kinase domain
- Exon 12: C-terminal tail
- Truncating mutations → earlier onset, more severe disease
- Missense mutations → variable penetrance
- Large deletions → often associated with additional phenotypes
Mutations in Neurodegeneration
While no direct causal BMPR2 mutations have been identified in neurodegenerative diseases, several risk-associated variants have been reported:
- Promoter polymorphisms: Altered expression levels
- Non-coding variants: Affect regulatory elements
- Somatic mutations: May occur in affected brain regions
Therapeutic Development
Small Molecule Approaches
Several pharmacological strategies are being developed:
BMP Agonists:
- BMP mimetic peptides
- Small molecule BMPR2 activators
- Antibody-based agonists
- Direct SMAD phosphorylation enhancers
- Inhibitors of negative regulators (SMAD6, SMAD7)
- SMAD4 co-activators
- BMP-SMAD pathway modulators
- Selective kinase inhibitors
- NF-κB pathway inhibitors
Gene Therapy Vectors
Viral vector approaches for BMPR2 delivery:
- AAV vectors: Various serotypes for CNS delivery
- Lentiviral vectors: For stable expression
- Non-viral approaches: Lipid nanoparticles, electroporation
Cell-Based Therapies
- BMP-expressing neural stem cells
- Engineered mesenchymal stem cells
- Induced neurons (iNeurons) with enhanced BMP signaling
Biomarkers and Diagnostics
Genetic Testing
- Diagnostic testing: For PAH families
- Predictive testing: For at-risk individuals
- Newborn screening: Not currently recommended
- Prenatal testing: Available for known mutations
Biomarker Development
Potential biomarkers for BMPR2-related conditions:
- Serum BMP levels: Correlation with disease activity
- SMAD phosphorylation: Biomarker of pathway activation
- Gene expression signatures: In peripheral blood cells
- Imaging biomarkers: For neurological involvement
Future Directions
Unanswered Questions
Key areas requiring further investigation:
- What are the exact molecular mechanisms linking BMPR2 dysfunction to neurodegeneration?
- How does BMPR2 cross-talk with other pathways in specific neuronal populations?
- Can BMPR2 modulation slow disease progression in animal models?
- What are the optimal delivery methods for BMPR2-targeted therapeutics?
Clinical Trials
Current and planned trials:
- BMP agonist trials in PAH (active)
- BMPR2 gene therapy trials (preclinical)
- Small molecule trials in neurodegeneration (planned)
References
Mechanistic Pathway Diagram
Genetic Variation and Disease Risk
Known Pathogenic Variants
BMPR2 harbors over 300 identified pathogenic variants:
| Variant Type | Frequency | Associated Phenotype |
|-------------|-----------|---------------------|
| Nonsense | 30% | PAH |
| Frameshift | 25% | PAH |
| Missense | 20% | PAH modifier |
| Splice site | 15% | PAH |
| Large deletions | 10% | PAH |
Functional Consequences
Different variant types lead to distinct functional outcomes:
- Truncating mutations: Cause haploinsufficiency through nonsense-mediated decay
- Missense mutations: Often result in dominant-negative effects
- Splice variants: May produce non-functional or partially functional receptors
Population Genetics
- Carrier frequency: ~1 in 500 for loss-of-function variants
- Penetrance: Highly variable (10-80%) depending on sex and environmental factors
- Founder effects: Identified in certain populations
Animal Models and Experimental Evidence
Mouse Models
Several BMPR2 mouse models have been developed:
- Conditional knockout: Brain-specific BMPR2 deletion
- Heterozygous models: Haploinsufficiency mimicking PAH
- Conditional rescue: Temporal BMPR2 restoration
Key Findings from Animal Studies
Comparative Biology
BMPR2 is evolutionarily conserved:
- Vertebrates: High conservation across mammals
- Drosophila: Homologous receptors (screw, thickveins)
- Zebrafish: bmpr2a and bmpr2b paralogs
Biomarker Potential
Diagnostic Biomarkers
BMPR2 measurement may aid in:
- Disease staging: Correlates with disease severity
- Subtype classification: Different expression patterns across diseases
- Progression markers: Changes over disease course
Therapeutic Response
BMPR2 as a treatment response marker:
- Target engagement: BMP pathway activation indicators
- Efficacy markers: Pre- and post-treatment levels
- Resistance indicators: Pathway dysregulation patterns
Summary
BMPR2 represents a critical hub in the BMP signaling network with significant implications for neurodegenerative disease pathogenesis. Its roles in neuroinflammation, neuronal survival, synaptic plasticity, and protein homeostasis make it an attractive therapeutic target. Understanding the cell-type-specific functions of BMPR2 and developing brain-penetrant modulators remain key priorities for translating this knowledge into clinical interventions.
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | genes-bmpr2 |
| kg_node_id | BMPR2 |
| entity_type | gene |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-5ef64109dce2 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'genes-bmpr2'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-genes-bmpr2?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[BMPR2 Gene](http://scidex.ai/artifact/wiki-genes-bmpr2)
http://scidex.ai/artifact/wiki-genes-bmpr2